Abstract
Target-specific imaging probes represent a promising tool in the molecular imaging of human cancer. Fluorescently-labeled target-specific probes are useful in imaging cancers because of their ability to bind a target receptor with high sensitivity and specificity. The development of probes relies upon preclinical testing to validate the sensitivity and specificity of these agents in animal models. However, this process involves both conventional histology and immunohistochemistry, which require large numbers of animals and samples with costly handling. In this chapter, we describe a novel validation tool that takes advantage of genetic engineering technology, whereby cell lines are transfected with genes that induce the target cell to produce fluorescent proteins with characteristic emission spectra, thus enabling their easy identification as cancer cells in vivo. Combined with multicolor fluorescence imaging, this can provide rapid validation of newly-developed exogenous probes that fluoresce at different wavelengths. For example, the plasmid containing the gene encoding red fluorescent protein (RFP) was transfected into cell lines previously developed to either express or not express specific cell surface receptors. Various antibody-based or ligand-based optical-contrast agents, with green fluorophores were developed to concurrently target cancer cells and validate their positive and negative controls, such as the β-d-galactose receptor, HER1, and HER2 in a single animal/organ. Spectrally-resolved multicolor fluorescence imaging was used to detect separate fluorescence emission spectra from the exogenous green fluorophore and RFP. Here, we describe the use of “co-staining” (matching the exogenous fluorophore and the endogenous fluorescent protein to the positive control cell line) and “counter-staining” (matching the exogenous fluorophore to the positive control and the endogenous fluorescent protein to the negative control cell line) to validate the sensitivity and specificity of target-specific probes. Using these in vivo imaging techniques, we are able to determine the sensitivity and specificity of target-specific optical contrast agents in several distinct animal models of cancer in vivo, thus exemplifying the versatility of our technique, while reducing the number of animals needed to conduct these experiments.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hama, Y., Urano, Y., Koyama, Y., Kamiya, M., Bernardo, M., Paik, R.S., et al. (2006) In vivo spectral fluorescence imaging of submillimeter peritoneal cancer implants using a lectin-targeted optical agent. Neoplasia 8(7), 607–612.
Kobayashi, K., Hama, Y., Koyama, Y., Barrett, T., Urano, Y., Choyke, P. (2007) Whole-body multicolor spectrally resolved fluorescence imaging for development of target-specific optical contrast agents using genetically engineered probes. Proc SPIE 6449, 644914.
Hama, Y., Urano, Y., Koyama, Y., Choyke, P.L., Kobayashi, H. (2007) d-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamine-conjugated serum albumin-rhodamine green. J Biomed Opt 12(5), 051501.
Longmire, M., Kosaka, N., Ogawa, M., Choyke, P.L., Kobayashi, H. (2009) Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer. Cancer Sci 100(6), 1099–1104.
Ogawa, M., Kosaka, N., Choyke, P.L., Kobayashi, H. (2009) In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 69(4), 1268–1272.
Kosaka, N., Ogawa, M., Longmire, M.R., Choyke, P.L., Kobayashi, H. (2009) Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer. J Biomed Opt 14(1), 014023.
Koyama, Y., Hama, Y., Urano, Y., Nguyen, D.M., Choyke, P.L., Kobayashi, H. (2007) Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res 13(10), 2936–2945.
Koyama, Y., Barrett, T., Hama, Y., Ravizzini, G., Choyke, P.L., Kobayashi, H. (2007) In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 9(12), 1021–1029.
Neher, R., Neher, E. (2004) Optimizing imaging parameters for the separation of multiple labels in a fluorescence image. J Microsc 213(Pt 1), 46–62.
Mansfield, J.R., Gossage, K.W., Hoyt, C.C., Levenson, R.M. (2005) Autofluorescence removal, multiplexing, and automated analysis methods for in-vivo fluorescence imaging. J Biomed Opt 10(4), 41207.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this protocol
Cite this protocol
McCann, T.E., Kosaka, N., Choyke, P.L., Kobayashi, H. (2012). The Use of Fluorescent Proteins for Developing Cancer-Specific Target Imaging Probes. In: Hoffman, R. (eds) In Vivo Cellular Imaging Using Fluorescent Proteins. Methods in Molecular Biology, vol 872. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-797-2_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-797-2_13
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-796-5
Online ISBN: 978-1-61779-797-2
eBook Packages: Springer Protocols